The doctor is officially in at the offices of JD Health, the online health unit of JD.com. That’s the latest word on the company whose planned IPO received a clean bill of health after the requisite hearing with the Hong Kong Stock Exchange, according to an announcement late Sunday.

The company, formally known JD Health International Inc., has not yet disclosed how much it hopes to raise from the listing, which was first disclosed when it filed a prospectus in late September. But a source close to the deal previously told Caixin it was aiming to raise between $1 billion and $2 billion.

The listing will come after JD Health picked up $940 million in its latest fundraising during the summer, which lifted the company’s value to about $18.6 billion.

JD Health’s revenue jumped 76% to 8.8 billion yuan ($1.3 billion) in the first half of this year, though it fell deeply into the red for the period with a loss of 5.4 billion yuan. But excluding a large one-time deduction related to fair value changes for its convertible preferred shares and other costs such as share-based payment expenses, the company reported an adjusted profit of 371 million yuan in the first half of 2020, up 46% year-on-year.

The company was the largest online drug seller in China last year, according to market research firm Frost & Sullivan, with about 72.5 million annual active users. It currently derives the lion’s share of its money from online drug sales.

Related: JD.com’s Latest Tonic Comes Bottled in Health Unit IPO 

Contact reporter Yang Ge (geyang@caixin.com)